IMTH (Innovative MedTech) Risk Assessment

View and export this data going back to 2007. Start your Free Trial

What is Innovative MedTech Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Innovative MedTech is: No Data: Cannot be evaluated.

Competitive Comparison of Innovative MedTech's Risk Assessment

For the Medical Instruments & Supplies subindustry, Innovative MedTech's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovative MedTech's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Innovative MedTech's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Innovative MedTech's Risk Assessment falls into.

Save Embed

;

Save Embed

;

Innovative MedTech (OTCPK:IMTH) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Innovative MedTech Risk Assessment Related Terms

Thank you for viewing the detailed overview of Innovative MedTech's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovative MedTech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Innovative MedTech Inc (OTCPK:IMTH) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

2310 York Street, Suite 200, Blue Island, IL, USA, 60406

Website

https://www.innovativemedtech.com

Innovative MedTech Inc is a provider of health and wellness services. It develops, manufactures, and sells a variety of medical devices and supplies, including blood collection and infusion products, surgical instruments, and wound care products. The company operates in two divisions: technology and devices and Adult Day Services.

Executives

Merle Griff	officer: Chief Executive Officer	2310 YORK ST, SUITE 200, BLUE ISLAND IL 60406
Eddie Dovner	10 percent owner	70 SE 4TH AVE, DELRAY BEACH FL 33483
Charles Everhardt	director, 10 percent owner, other: Chairman of the Board	2310 YORK ST, STE 200, BLUE ISLAND IL 60406
Arthur Friedman	10 percent owner	280 MADISON AVE #1007, NEW YORK NY 10016
Marcia Roberts	10 percent owner	280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Michael Jordan Friedman	director, 10 percent owner, officer: President & CEO	280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Illuminate, Inc.	10 percent owner	881 KENNEDY BLVD., JERSEY CITL NJ 07002
A William Bodine	director, officer: CFO	280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Dominick M Cingari	director, officer: COO	280 MADISON AVENUE, SUITE 1005, NEW YORK NY 10016
Jay Odintz	director	280 MADISON AVENUE, NEW YORK NY 10016
Vincent L Verdiramo	director, officer: President	3163 KENNEDY BLVD, JERSEY CITY NJ 07306